AAV RNAi Delivery for DMPK Silencing in Myotonic Dystrophy

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for myotonic dystrophy, particularly DM1, are lacking, and existing mouse models do not accurately recapitulate the disease, complicating the development of effective therapeutic drugs.

Innovation Solution

RNA interference-based products using adeno-associated viruses (AAV) to deliver inhibitory RNAs, such as siRNAs and shRNAs, targeting the DMPK gene and CTG repeat expansions in the 3' untranslated region to inhibit DMPK expression.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If RNA interference-based products using AAV to deliver inhibitory RNAs are used to target DMPK gene and CTG repeat expansions, then DMPK expression is reduced and CTG repeat expansions are interfered with, providing therapeutic effect, but the complexity of delivering and maintaining specific RNA targeting increases

Engineering Contradiction:

Improvetherapeutic effectVSAvoiddelivery system complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent uses adeno-associated virus (AAV) as an intermediary vector to deliver inhibitory RNAs (siRNAs, shRNAs) to target DMPK gene expression and CTG repeat expansions. The AAV vector serves as a mediator that carries the therapeutic RNA molecules into target cells, enabling specific gene silencing without directly modifying the genome. This resolves the complexity by providing a well-established delivery platform that can be optimized for tissue specificity and safety.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent employs different types of inhibitory RNAs (siRNAs, shRNAs, miRNAs) with varying molecular structures and mechanisms of action. By changing the parameter of RNA type, the system can target different aspects of DMPK expression - some RNAs target the mRNA directly for degradation, while others target the repeat expansions. This parameter variation allows optimization of therapeutic efficacy for different disease stages and patient profiles.

Inventive Principle:

Principle #35Parameter changes

2Adaptability or versatility

If existing mouse models are used for DM1 research, then animal testing is possible, but they do not accurately recapitulate the disease features, complicating drug testing

Engineering Contradiction:

Improvedisease modeling capabilityVSAvoiddisease recapitulation accuracy

Core Design Contradiction:

Adaptability or versatilityVSMeasurement precision

Solution Approach 1:

The patent creates a more accurate mouse model by copying the essential feature of DM1 - the CTG repeat expansion in the DMPK gene - into the mouse genome. This involves introducing the expanded repeat sequence into mouse DMPK gene, thereby replicating the molecular defect that causes the disease. The model maintains mouse physiology while incorporating the human-relevant genetic mutation, enabling better translation of drug efficacy to human treatment.

Inventive Principle:

Principle #26Copying

3Ease of operation

If symptom management is used instead of curative treatment, then patient quality of life can be maintained, but the progression of the disease continues unchecked

Engineering Contradiction:

Improvetreatment accessibilityVSAvoiddisease progression control

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The patent extracts and targets the specific harmful element - the CTG repeat expansions and DMPK mRNA - using RNA interference. By taking out the toxic repeats from the gene expression process and degrading the DMPK mRNA, the system addresses the root cause of the disease rather than merely managing symptoms. This extraction approach enables potential cure while maintaining accessibility through established RNA delivery technologies.

Inventive Principle:

Principle #2Taking out (Extraction)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The method effectively reduces DMPK gene expression and interferes with CTG repeat expansions, providing a potential therapeutic approach for myotonic dystrophy and offering a more accurate mouse model for drug testing.

Implementation Method 1

RNA interference-based products and methods for inhibiting the expression and/or interfering with the repeat expansion of the CTG trinucleotide repeat in the 3' untranslated region of the DMPK gene

Methodology Applied

Scientific EffectRNA interference:

Implementation Method 2

The DMPK inhibitory RNAs of the disclosure include, but are not limited to, antisense RNAs, small inhibitory RNAs (siRNAs), short hairpin RNAs (shRNAs), small nuclear RNAs (snRNAs or U-RNAs), or artificial microRNAs (DMPK miRNAs) that inhibit expression of DMPK

Methodology Applied

Scientific EffectGene silencing:

Data Source

PatentUS20260049320A1Recombinant virus products and methods for inhibiting expression of dystrophia myotonica protein kinase and/or interfering with a trinucleotide repeat expansion in the 3' untranslated region of the DMPK gene

Publication Date: 2026.02.19 RES INST AT NATIONWIDE CHILDRENS HOSPITAL

AI summary

The present disclosure relates to RNA interference-based methods for inhibiting the expression of the dystrophia myotonia protein kinase (DMPK) gene. Recombinant adeno-associated viruses of the disclosure deliver DNAs encoding inhibitory RNAs that knock down the expression of DMPK or interfere with the expression of the CTG repeat associated with myotonic dystrophy type-1 (DM1). The methods have application in the treatment of myotonic dystrophies, including DM1, and other disorders associated with aberrant DMPK expression.